Early oral anticoagulation is non-inferior to delayed treatment in patients with ischemic stroke and atrial fibrillation
1. Early DOAC therapy within 4 days was non-inferior to delayed therapy for the composite outcome of recurrent ischemic or ...
Tag: anticoagulant
#VisualAbstract Edoxaban Monotherapy has Lower Risks for Atrial Fibrillation and Stable Coronary Artery Disease than Dual Antithrombotics
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Asundexian does not reduce the risk of recurrent strokes after non-cardioembolic ischemic stroke
1. The composite of MRI-detected brain infarcts and symptomatic ischemic stroke was comparable across different doses of asundexian and placebo. ...
Rivaroxaban associated with significantly increased risk of major ischemic or hemorrhagic events versus apixaban in patients with atrial fibrillation
1. In patients with atrial fibrillation over 65, treatment with rivaroxaban compared to apixaban was associated with a significantly increased ...
![siRNA against antithrombin alleviates symptoms of hemophilia [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2015/04/clot-CCWiki-350x250.jpg)
Therapeutic anticoagulation increases bleeding risk without improvements in clinical outcomes in patients admitted for COVID-19 and elevated D-dimer
1. Therapeutic anticoagulation with rivaroxaban or enoxaparin did not improve clinical outcomes and increased bleeding compared with prophylactic anticoagulation. 2. ...
Rivaroxaban and warfarin have similar safety and efficacy in mild atrial fibrillation-related ischemic stroke
1. In this randomized controlled trial, rivaroxaban and warfarin were similar in safety and efficacy when used to prevent early ...
The EINSTEIN-DVT trial: Rivaroxaban in acute deep-vein thrombosis [Classics Series]
Image: PD 1. Rivaroxaban is non-inferior to standard therapy of enoxaparin and vitamin K antagonist in treating acute, symptomatic deep-vein ...